The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk

References

• Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010 Nov 2 (Epub ahead of print).
   PubMedGoogle Scholar
• Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, . Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–74.
   PubMed Web of Science ®Google Scholar
• Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, . Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–9.
   PubMed Web of Science ®Google Scholar
• Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674–79.
   PubMedGoogle Scholar
• Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, . The diagnostic value of biomarkers (Steato Test) for the prediction of liver steatosis. Comp Hepatol. 2005;4:10.
   PubMedGoogle Scholar
• Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology. 2010;10:98.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, . Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42:503–8.
   PubMedGoogle Scholar
• Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, . Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–72.
   PubMed Web of Science ®Google Scholar
• Carvalho J, Barengo NC, Conceição R, Tuomilehto J, Santos R. The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis. Ann Med. SANN-2010-0186.R2.
   Google Scholar
• Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26:725–31.
   PubMed Web of Science ®Google Scholar
• Rathmann W, Martin S, Haastert B, Icks A, Holle R, Lowel H, . Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey. 2000. Arch Intern Med. 2005;165:436–41.
   PubMed Web of Science ®Google Scholar
• Saaristo T, Peltonen M, Lindstrom J, Saarikoski L, Sundvall J, Eriksson JG, . Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2:67–72.
   PubMedGoogle Scholar
• Franciosi M, Berardis G, De Rossi MC, Sacco M, Belfiglio M, Pellegrini F, . Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28:1187–94.
   PubMed Web of Science ®Google Scholar
• Silventoinen K, Pankow J, Lindström J, Jousilahti P, Hu G, Tuomilehto J. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil. 2005;12:451–58.
   PubMedGoogle Scholar
• Bergmann A, Li J, Wang L, Schulze J, Bornstein SR, Schwarz PE. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res. 2007;39:677–82.
   PubMed Web of Science ®Google Scholar
• Lin JW, Chang YC, Li HY, Chien YF, Wu MY, Tsai RY, . Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney disease in Taiwanese. Diabetes Care. 2009;32:2294–6.
   PubMedGoogle Scholar
• Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011; 92:46–52.
   PubMed Web of Science ®Google Scholar
• Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, . Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2010 Dec 6 (Epub ahead of print).
   PubMedGoogle Scholar
• Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, . Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2008;31:2056–61.
   PubMed Web of Science ®Google Scholar
• Balkau B, Lange C, Vol S, Fumeron F, Bonnet F; Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol. 2010;10:56.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, . Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537–44.
   PubMed Web of Science ®Google Scholar
• Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care. 2006;29:151–3.
   PubMed Web of Science ®Google Scholar
• Bozorgmanesh M, Hadaegh F, Azizi F. Diabetes prediction, lipid accumulation product, and adiposity measures; 6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis. 2010;9:45.
   PubMed Web of Science ®Google Scholar
• Bozorgmanesh M, Hadaegh F, Azizi F Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study. Lipids Health Dis. 2010;9:100.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48:1–26.
   PubMed Web of Science ®Google Scholar
• Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol. 2009;44:1064–70.
   PubMedGoogle Scholar
• Musso G, Gambino R, Cassader M. The need for a three-focused approach to non-alcoholic fatty liver disease (NAFLD). Hepatology. 2011;53:1773.
   PubMed Web of Science ®Google Scholar